Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Down 35.9% in February

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 170,700 shares, a drop of 35.9% from the January 31st total of 266,500 shares. Based on an average daily volume of 400,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.0% of the shares of the company are sold short.

Sensei Biotherapeutics Stock Down 7.5 %

Shares of NASDAQ:SNSE opened at $0.43 on Tuesday. Sensei Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.94. The firm’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.51. The company has a market cap of $10.84 million, a price-to-earnings ratio of -0.36 and a beta of 0.17.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Sensei Biotherapeutics in a research note on Wednesday, January 8th.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd grew its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the quarter. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.